Skip to main content
. 2020 Nov 4;2020(11):CD013004. doi: 10.1002/14651858.CD013004.pub2

1.1. Analysis.

1.1

Comparison 1: Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), Outcome 1: Mortality from cardiovascular causes (follow‐up range 19 months to 23 months)